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Abstract
Background: Despite better renal function following nephron-sparing surgery (NSS)
relative to radical nephrectomy (RN), there is no consensus with respect to the long-term
sequelae associated with surgery.
Objective: To investigate the effect of surgery and the temporal pattern of two different
cardiovascular event (CVe) categories after NSS versus RN.
Design, setting, and participants: We collected data of 898 patients with cT1–2 N0 M0
renal mass and no history of CVe treated with NSS versus RN. CVe categories were
dichotomised in (1) de novo hypertension (HT) and (2) other major cardiovascular
events (MCEs).
Outcome measurements and statistical analysis: Multivariable competing regression
analyses (MVAs) tested the adjusted effect of surgery type on each CVe category.
Results and limitations: Among patients treated with RN, 38% of HT events occurred
immediately after surgery. Conversely, in NSS counterparts, the onset of HT was diluted
over the years after surgery (10% of HT events in the first 6 mo). When an MCE was
considered, an increasing long-term time-dependent prevalence of the outcome was
observed in both groups, with no statistically significantly difference between NSS and RN.
At MVA, RN was associated with a higher HT risk (hazard ratio [HR] 2.89; p = 0.006) than
but a similar MCE risk (HR 0.85; p = 0.6) to NSS.
Conclusions: Relative to RN, NSS showed an independent protective effect on HT but
not on MCEs. In patients with no history of preoperative HT or MCEs, the onset of HT after
RN is a very early event, due probably to the acute loss of renal parenchyma. This is not
the case for the other cardiovascular morbidity, which develops in the long-term period,
regardless of the type of surgery performed.
Patient summary: In renal cancer patients without a medical history of cardiopathy,
preserving healthy kidney tissue at surgery is associated with a decreased risk of
developing postoperative hypertension.
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.. Department of Urology, San Raffaele Scientific Institute, via Olgettina 60,
+39 02 2643 7286; Fax: +39 02 2643 7298.
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The equipoise in oncological outcomes between nephron-
sparing surgery (NSS) and radical nephrectomy (RN) for
patients with clinically localised kidney cancer [1] is well
established. For this reason—according to all available
international guidelines—if a healthy part of the kidney
can be safely spared, the treatment of choice is NSS. Notably,
better renal function following NSS represents the most
widely accepted clinical benefit of NSS compared with RN
[2]. Moreover, it has been suggested that NSS may decrease
the risk of end-stage renal disease and cardiovascular
events (CVe) after surgery [1–5].
To better understand the natural history of cardiovascu-
lar morbidity after surgery, we created a multi-institutional
collaboration to investigate the effect of NSS on two specific
cardiovascular categories and to analyse the temporal
pattern of presentation of all the events.
2. Patients and methods
2.1. Population
A multi-institutional collaboration of three tertiary care centres enabled
the collection into a prospectively maintained database of 2092 conse-
cutive patients diagnosed with a single clinical T1–2 N0 M0 renal mass
who underwent elective surgical treatment between 1987 and 2016. To
rule out any potential confounding effect of a pre-existing condition of
cardiovascular morbidity, we have excluded from our analysis all cases
with a previous history of either hypertension (HT) or CVe (n = 1173).
Patients with missing follow-up information were also excluded (n = 21).
After these exclusions, the final cohort consisted of 898 patients with
cT1–2 N0 M0 renal mass and no baseline CVe.
2.2. Clinical and pathological evaluation
Clinical tumour size was calculated based on preoperative imaging and
was defined as the greatest tumour diameter in centimetres. The
estimated glomerular filtration rate (eGFR) was calculated with the
Chronic Kidney Disease Epidemiology Collaboration formula in patients
younger than 70 yr old, while the Berlin Initiative Study (BIS1) formula
was used for older patients (70 yr).
2.3. Outcomes
The outcomes considered for this study were de novo HT and major
cardiovascular events (MCEs). HT was defined as a diagnosis of HT
requiring at least one drug, while coronary heart disease, cerebrovascu-
lar event, thromboembolic event, dysrhythmias, and peripheral arterio-
pathy were considered as MCEs. The treating physician or cardiologist
defined the need for therapy in case of HT and characterisation of MCE
type. Those endpoints were collected by scrutinizing subsequent
hospital admission charts or during periodic follow-up visits or,
alternatively, by phone call if a patient was referred to another hospital
after surgery. In patients with multiple MCE, only the first occurred after
surgery was taken into consideration for the purpose of our analysis, to
account for the competing nature of the two conditions.
2.4. Covariates
Analyses were adjusted for the following covariates: age at surgery,
gender, preoperative eGFR, comorbidities (defined according to theCharlson comorbidity index [CCI]) [6], diabetes, smoking history (active
smoker vs former smoker vs no smoking history), clinical tumour size,
and year of surgery.
2.5. Statistical analyses
Statistical analyses as well as reporting and interpretation of the results
were conducted according to established guidelines [7] and consisted of
three steps. First, medians and interquartile ranges were reported for
continuous variables, or frequencies and proportions were reported for
categorical variables. Mann-Whitney and chi-square tests were used to
compare the statistical significance of differences in the distribution of
continuous and categorical variables, respectively, between cases treated
with NSS versus RN.
Second, given the competing nature of the outcomes examined,
smoothed Poisson cumulative curves were used to assess the rates of HT
and MCEs.
Third, the impact of treatment modality, namely, NSS versus RN, on
the study outcomes was estimated using a multivariable competing
regression analysis (MVA) after adjustment for all the study covariates.
All statistical tests were performed using the RStudio graphical interface
v.0.98 for R software environment v.3.0.2 with the following libraries,
packages, and scripts: Hmisc, plyr, stats, rms, and cmprsk. All tests were
two sided, with a significance level set at p < 0.05.
3. Results
RN and NSS were performed, respectively, in 36% (n = 326)
and 64% (n = 572) of the patients (Table 1). Patients treated
with NSS were diagnosed with a smaller tumour (median
clinical size 3 vs 6 cm; p < 0.0001) and had higher eGFR at
baseline (median eGFR 93 vs 87; p < 0.0005) relative to
their RN counterparts.
Median follow-up was 58 mo (interquartile range 22–
115). Figs. 1 and 2 depict the smoothed Poisson cumulative
prevalence of HT and MCEs in NSS and RN patients,
respectively. The 5-yr HT and MCE rates were, respectively,
3.3% and 6.3% in NSS cases versus 5.1% and 4.2% in RN cases.
In NSS, the onset of HT was diluted over the years after
surgery (10% of all HT events in the first 6 mo; Fig. 1, red
curve), while 38% of all HT events in RN occurred in the first
6 mo after surgery (Fig. 2, red curve). Conversely, the vast
majority of MCEs accumulate regularly over time, regardless
of the type of surgery (Figs. 1 and 2, grey curves). At MVA,
after accounting for all the potential confounders, RN was
associated with a higher risk of HT (hazard ratio 2.89; 95%
confidence interval 1.35–6.17; p = 0.006) but a similar MCE
risk (hazard ratio 0.85; 95% confidence interval 0.4–1.17;
p = 0.66) relative to NSS (Table 2).
4. Discussion
NSS is currently the standard of care for patients who are
candidates for surgery for a clinical T1 renal mass, when
technically feasible [1,8,9]. NSS is equivalent to RN in terms
of cancer control [10–14] but is associated with better renal
function [15,16]. Recent data have suggested a potential
benefit in terms of decreasing the risk of subsequent CVe in
patients treated with NSS in comparison with RN [16–
19]. Many mechanisms have been suggested to explain why
Table 1 – Descriptive characteristics of 898 T1–T2 N0 M0 RCC
patients treated with NSS (n = 572) or RN (n = 326) at three tertiary
care institutions
Variable NSS
(n = 572, 64%)
RN
(n = 326, 36%)
p value
Age 0.6
Median 57 56
IQR 46–66 47–65
Gender 0.2
Male 361 (63) 221 (68)
Female 211 (37) 105 (32)
CCI 0.6
Median 0 0
IQR 0–2 0–1
Preoperative eGFR <0.0005
Median 93 87
IQR 77–103 71–99
Diabetes 0.31
No 531 (93) 309 (95)
Yes 41 (7) 17 (5)
Smoking status 0.78
No smoking history 344 (60) 198 (61)
Active smoker 100 (17) 61 (19)
Former smoker 128 (22) 67 (21)
Clinical size <0.0001
Median 3 6
IQR 2.4–4 4.6–7.5
Year of surgery <0.0001
Median 2009 2005
IQR 2007–2011 1999–2010
CCI = Charlson comorbidity index; eGFR = estimated glomerular filtration
rate; IQR = interquartile range; NSS = nephron-sparing surgery; RCC = renal
cell carcinoma; RN = radical nephrectomy.
Data are further stratified according to the treatment delivery.
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increased cardiovascular morbidity (eg, endothelial dys-
function, increased arterial calcification and stiffness
[20,21], increased levels of inflammatory factors [22], high
apolipoprotein levels, anaemia [23], and left ventricular
hypertrophy [24,25]). Nonetheless, all available data are
invariably based on nephropathic patients, living donors,
and transplant recipients, and there is a paucity of data in
the context of kidney cancer patients. Remarkably, the latter
should be regarded as a significant different clinical
scenario, due to the differences observed in age and
comorbidity profile (eg, diabetes, chronic kidney disease,
etc.) that prevent any clinically valid generalisation of the
same research findings.
Many previous reports revealed a greater number of
cardiovascular events in patients treated with RN than in
those treated with NSS [26–28], although controversies are
still there. Huang et al. [27] analysed the Surveillance,
Epidemiology, and End Results (SEER)-Medicare cancer
registry, and collected data for 2991 patients treated with
NSS (19%) or RN (81%) between 1995 and 2002. After a mean
follow-up period of 43 mo, they reported a 20% CVe rate
after surgery, with a 1.4-fold greater number of events after
RN (p < 0.05). However, the results could not be adjusted for
potential confounders in patient selection. In this setting, a
recent European collaboration conducted a multi-institu-
tional retrospective study, which included 1331 patientswith a clinical T1a–T1b N0 M0 renal mass and normal renal
function before surgery, confirming a higher CVe risk in RN
patients (n = 462, 35%) than in their NSS counterparts
(n = 869, 65%) [26]. Many criticisms were raised after the
publication of the report. Specifically, it was suggested that
potential selection biases might have flawed the results due
to fact that the curves depicting the rate of CVe between NSS
and RN showed an early separation immediately after the
surgery. Recently, Yap et al. [29] conducted a large
retrospective study in 11 937 patients (who underwent
either NSS or RN between 1995 and 2010) selected using
linked administrative databases in the province of Ontario,
Canada. After a median follow-up of 57 mo, they established
a benefit of NSS after controlling for competing risks of
death for myocardial infarction (p < 0.05). However, neither
HT nor any other type of CVe, other than myocardial
infarction, was considered as an outcome.
To address the need of clarification in this topic, Wang
et al. [30] conducted a meta-analysis of renal function and
cardiovascular outcomes in patients submitted to either
NSS or RN for renal tumour. Overall, 26 studies were pooled
for new-onset chronic kidney disease, and six studies were
pooled for cardiovascular outcomes; NSS was shown to
correlate with a 73% risk reduction of new-onset chronic
kidney disease in all included patients (hazard ratio [HR]
0.27; p < 0.0001) and a 65% risk reduction in patients with
tumours >4 cm (HR 0.35; p < 0.0001) compared with RN. It
was also shown that there were no significant differences
between groups regarding postoperative CVe (HR 0.86;
p = 0.2) and cardiovascular death (HR 0.79; p = 0.2).
After accounting for both clinical and tumour character-
istics, we were able to demonstrate that NSS independently
decreases HT risk relative to RN (RN HR 2.89; 95%
confidence interval [CI] 1.35–6.17; p = 0.006), while no
difference was found in MCE risk between the two groups
(HR 0.85; 95% CI 0.4–1.17; p = 0.6). In addition, we
demonstrated that while many HT events in RN occur in
the first 6 mo after surgery (38% of all HT events; Fig. 2), in
NSS the onset of HT has been diluted over the years after
surgery (Fig. 1, red curve). This was not the case for MCEs,
where the events occurred later during the follow-up, with
an increasing time-dependent prevalence in both the
groups (Fig. 1 and 2, grey curves). These findings were
further confirmed at MVA, after accounting for potential
confounders, where patients who underwent RN were
shown to have a higher HT risk (HR 2.89; 95% CI 1.35–6.17;
p = 0.006) than but a similar MCE risk (HR 0.85; 95% CI 0.4–
1.17; p = 0.66) to their NSS counterparts (Table 2). Since
some events were recorded immediately after surgery, we
could not include in the adjusted model the variable
depicting postoperative eGFR to limit the collinearity and to
avoid the inclusion of a variable that might have affected the
outcomes only in those patients with no events in the first
months after surgery.
One of the possible pathophysiological mechanisms
beyond such a finding may be related to the acute loss of
half of nephrons, which happens in RN patients. In order to
compensate for the parenchymal loss and maintain the
preoperative filtration function, the remaining kidney
Fig. 1 – Smoothed Poisson cumulative curves depicting hypertension (HT) and major cardiovascular event (MCE) rates in 572 patients diagnosed with a
single clinical T1–2 renal mass who underwent NSS between 1987 and 2016. The 5-yr HT and MCE rates are 3.3% and 6.3%, respectively. NSS = nephron-
sparing surgery.
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compensatory function of the remaining glomeruli
[31]. We suppose that this might be achieved through a
rapid increase in the renin-angiotensin-aldosterone system
(RAAS) activation, with an increased renin production in the
kidney. Clearly increased RAAS activation could be the
direct culprit of the increased HT risk in these patients,
causing the hypertensive state in those already more
susceptible to a cardiovascular homeostasis alteration
[32]. This hypothesis is further supported by the fact that
HT is an early event after surgery: the RAAS activation
would be an immediate event after the nephrectomy, and it
stands to reason that the HT onset would follow shortly
thereafter. Although further research is needed to confirm
such a hypothesis, the use of an angiotensin-converting
enzyme inhibitor in patients who undergo nephrectomy
might represent a potentially useful tool for clinical
practice.
Moreover, it was long believed that living kidney donors
(LKDs), who are subjected to the same parenchymal loss as
patients submitted to RN for kidney cancer, were not exposed
to an increased CVe rate [33,34], but there is mounting
evidence that these patients are subjected to an increased CVerisk too. Moody et al. [35] demonstrated that unilateral
nephrectomy in healthy individuals is associated with
structural and functional cardiovascular abnormalities (myo-
cardial deformation, increased aortic stiffness, and increase in
left ventricle mass) within 1 yr. In addition, Mjøen et al. [36]
compared LKDs with healthy controls and observed a
significant increase in cardiovascular mortality (HR 1.40;
95% CI 1.03–1.91; p = 0.03). We suppose that in LKDs,
cardiovascular alteration, and following increased CVe risk,
might recognise the same causes as those in individuals
submitted to RN, due to the fact that both populations undergo
a sudden nephron loss [37]. In case of surgery for kidney
tumour, such mechanisms are further augmented by the fact
that kidney cancer patients are older and more comorbid than
their LKD counterparts, and these aspects are well-known
detrimental factors for the development of HT and MCEs.
For the first time, our study provides an adjusted analysis
of the timing and risk of development of HT and MCEs after
NSS or RN. We demonstrated a different temporal pattern of
presentation between NSS and RN for HT development,
which suggests novel pathophysiological mechanisms
beyond the functional outcomes of kidney tumour patients
treated with surgery. Besides these merits, the major
Fig. 2 – Smoothed Poisson cumulative curves depicting hypertension (HT) and major cardiovascular event (MCE) rates in 326 patients diagnosed with a
single clinical T1–2 renal mass who underwent RN between 1987 and 2016. The 5-yr HT and MCE rates are 5.1% and 4.2%, respectively. RN = radical
nephrectomy.
Table 2 – Multivariable competing risk regression analysis
addressing the effect of NSS versus RN on the risk of developing HT
or MCEs in patients with no cardiovascular history after
adjustment for clinical and pathological confounders
Predictors MVA predicting HT MVA predicting MCE
HR (95% CI) p value HR (95% CI) p value
Approach
NSS Ref. Ref.
RN 2.89 (1.35–6.17) 0.006 0.85 (0.4–1.78) 0.7
Age (yr) 1.02 (0.99–1.05) 0.2 1.04 (0.99–1.08) 0.09
Gender
Male Ref. Ref.
Female 1.16 (0.63–2.16) 0.6 0.71 (0.35–1.42) 0.3
CCI 1.02 (0.73–1.44) 0.9 1.07 (0.78–1.48) 0.7
Preoperative eGFR 0.98 (0.96–1) 0.1 0.99 (0.97–1) 0.09
Diabetes
No Ref. Ref.
Yes 0.84 (0.23–3.14) 0.8 2.16 (0.86–5.43) 0.1
Smoking status
No smoking history Ref. Ref.
Active smoker 0.7 (0.3–1.64) 0.4 1 (0.47–2.12) 0.9
Former smoker 0.72 (0.31–1.67) 0.4 0.92 (0.45–1.9) 0.8
Clinical size 0.94 (0.82–1.07) 0.3 0.98 (0.84–1.15) 0.8
Year of surgery 1.16 (1.08–1.25) 0.0006 1.09 (1.02–1.18) 0.01
CCI = Charlson comorbidity index; CI = confidence interval; eGFR = estimated
glomerular filtration rate; HR = hazard ratio; HT = hypertension; MCE = major
cardiovascular event; MVA = multivariable analyses; NSS = nephron-sparing
surgery; Ref. = reference; RN = radical nephrectomy.
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comparison. Since it is possible that the characteristics of the
patients (CCI, presence of HT or diabetes, etc.) treated with
NSS and RN have been changing over the years, and that the
accuracy of the treating physician to detect de novo HT or
other MCEs has been improving over the last decade, we
decided to adjust all the analyses for the year of surgery to
correct them for these possible aspects. Moreover, within this
data source, we could not test the mutual causal relationship
between the postoperative renal function detriment and the
risk of CVe. Finally, as was the case for most data available on
the topic, the results could not be adjusted for other
important risk factors for cardiovascular disease such as
hyperlipidaemia, exercise activity, and alcohol use.
5. Conclusions
In renal cell carcinoma patients without preoperative
cardiovascular morbidity, the effect of surgical approach
varies according to the type of CVe that is considered.
Relative to RN, NSS showed an independent protective
effect on HT but not on MCEs. In patients with no history of
preoperative HT or MCEs, the onset of HT after RN is an
early event, due probably to the acute loss of renal
parenchyma.
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